Wednesday, January 07, 2026 | 11:27 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Letter to BS: Undue haste in making Covid-19 vaccine will be risky

I think the deadline that the Indian Council of Medical Research has declared is unrealistic

Coronavirus, vaccine, covid, drugs, Sepsivac, clinical trials
premium

Business Standard
It will be an honour for us if India becomes the first country to come out with a vaccine against Covid-19. But as a young citizen, I think the deadline that the Indian Council of Medical Research has declared is unrealistic. If the deadline declaration is only due to political and public pressure, it’s a big concern for everyone. From my readings I found that under normal circumstances, vaccine trials require a certain period — mostly the time is in years. 

Often, there are unexpected effects of a vaccine that are visible years after administration and also no one can guarantee the durability of a new vaccine. That being the case, any undue haste in the production of a Covid-19 vaccine may not only increase the risk of side-effects but also pose a threat to life.

Harshal Suresh Dasale    Pune


Letters can be mailed, faxed or 
e-mailed to: The Editor, 
Business Standard,Nehru House, 
4 Bahadur Shah Zafar Marg, 
New Delhi 110 002 
Fax: (011) 23720201  ·  E-mail: letters@bsmail.in
All letters must have a postal address and telephone number